Alex Zhavoronkov

Last updated

Alex Zhavoronkov
Alex Zhavoronkov at WEF 2024 Annual Meeting of the New Champions.png
At a WEF meeting in June 2024
Born
Riga, Latvia [1] [2]
Alma mater Queen's University at Kingston
Johns Hopkins University (JHU) [3]
Known forThe Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy
Scientific career
Fields aging, regenerative medicine, drug development, artificial intelligence
Institutions Insilico Medicine, Biogerontology Research Foundation

Alex Zhavoronkov (born Aleksandrs Zavoronkovs) [3] is a Latvian-born scientist and author working in biotechnology, regenerative medicine, and aging economics. He is the founder and CEO of Insilico Medicine, [4] [5] [6] and as of 2024, was also the director of the Biogerontology Research Foundation, [7] [8] a UK-based think-tank for aging research. Zhavoronkov has published a substantial number of papers, and books including The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy. [9] [10]

Contents

Biography

Early life, education, and career

Born in Latvia, [1] [2] [6] Zhavoronkov received two bachelor's degrees from Queen's University, [3] and worked in graphics processing before moving to the biotechnology field. [11] He received a master's degree in biotechnology from Johns Hopkins University, [6] [11] and a PhD in physics and mathematics from Moscow State University. [3] In the mid 2010s, he was an adjunct professor at the Moscow Institute of Physics and Technology. [12] As of 2024, he was an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging. [13] Zhavoronkov was named as a co-inventor on a patent issued in May 2013 for "systems and methods for communicating with a computer using brain activity patterns". [14] [15]

AI and medical research

In 2014, Zhavoronkov began work towards using "massive data sets and Al to significantly speed up the drug discovery process", [16] and established Insilico at Johns Hopkins University in Baltimore. [6] [11] [16] [17] [18] Tony Robbins and Peter Diamandis were early investors in Zhavoronkov's efforts. [16] Robbins wrote of Zhavoronkov that "researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology". [16]

In November 2017, Zhavoronkov proposed the application of the deep learning techniques and blockchain technology for managing human life data. [19] [20] [21]

In 2022, Zhavoronkov participated in a round of financing for Insilico Medicine that raised $60 million for the venture. [22] Zhavoronkov asserted at the time that the industry was "in 'biotechnology winter' where many companies are running out of cash and are dying", and that his fundraising was positioning the company for a coming "biotech spring". [22] AI writer Calum Chace described Zhavoronkov at the time as well-known within the longevity community "for his relentless focus". [1] In February 2023, Wesley J. Smith, writing for National Review , sharply criticized comments by Zhavoronkov, who had observed that organ transplants used to facilitate life extension could someday be provided by using human clones generated without cognitive functions. [23]

In June 2023, Zhavoronkov led Insilico's development of what he described as "the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients". [24] In 2024, he moved the headquarters of the company to Boston, Massachusetts. [25]

Other AI and internet activities

In 2016, Zhavoronkov was the chief science officer for Beauty.AI, an artificial intelligence technology that evaluate people's external appearance through certain algorithms. In this role, he responded to concerns about ethnic bias in results generated by the platform by attributing them to a lack of data provided to it. [26] [27]

In 2022, Zhavoronkov was an author of a paper titled Rapamycin in the context of Pascal's Wager: generative pre-trained transformer perspective, which was described as one of the first peer-reviewed published papers to formally credit ChatGPT as a coauthor. [28] Zhavoronkov reported that when he asked ChatGPT itself whether it should be named as a coauthor, "it responded with multiple compelling reasons as to why it should not". [28]

In May 2024, Zhavoronkov was noted to have funded production of a realistically animated rendition of a head transplant, with the face of the transplant subject being recognized as Zhavoronkov's own. This became a viral video on social media. [29]

Publications

Since 2010, Zhavoronkov has authored or co-authored over 250 scientific articles published in refereed journals and referenced in PubMed. [30] [31]

Books
Articles

Related Research Articles

Artificial intelligence (AI), in its broadest sense, is intelligence exhibited by machines, particularly computer systems. It is a field of research in computer science that develops and studies methods and software that enable machines to perceive their environment and use learning and intelligence to take actions that maximize their chances of achieving defined goals. Such machines may be called AIs.

<span class="mw-page-title-main">Life extension</span> Concept of extending human lifespan by improvements in medicine or biotechnology

Life extension is the concept of extending the human lifespan, either modestly through improvements in medicine or dramatically by increasing the maximum lifespan beyond its generally-settled biological limit of around 125 years. Several researchers in the area, along with "life extensionists", "immortalists", or "longevists", postulate that future breakthroughs in tissue rejuvenation, stem cells, regenerative medicine, molecular repair, gene therapy, pharmaceuticals, and organ replacement will eventually enable humans to have indefinite lifespans through complete rejuvenation to a healthy youthful condition (agerasia). The ethical ramifications, if life extension becomes a possibility, are debated by bioethicists.

Daclizumab is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab works by binding to CD25, the alpha subunit of the IL-2 receptor of T-cells.

Following is a list of topics related to life extension:

Charles Thomas Caskey, also known as C. Thomas Caskey, was an American internist who has been a medical Geneticist and biomedical researcher and entrepreneur. He was a Professor of Molecular and Human Genetics at Baylor College of Medicine, and served as editor of the Annual Review of Medicine from 2001 to 2019. He was a member of the editorial boards of the Proceedings of the National Academy of Sciences, Science, the Encyclopedia of Molecular Medicine and numerous other medical and scientific journals.

Rovelizumab, also known as LeukArrest and Hu23F2G, is a humanized monoclonal antibody which was an experimental immunosuppressive drug. It was developed by Icos to treat patients with haemorrhagic shock.

Artificial intelligence (AI) has been used in applications throughout industry and academia. In a manner analogous to electricity or computers, AI serves as a general-purpose technology. AI programes emulate perception and understanding, and are designed to adapt to new information and new situations. Machine learning has been used for various scientific and commercial purposes including language translation, image recognition, decision-making, credit scoring, and e-commerce.

<span class="mw-page-title-main">Patrick Soon-Shiong</span> South African and American doctor (born 1952)

Patrick Soon-Shiong is a South African and American businessman, investor, medical researcher, and transplant surgeon. He is the inventor of the drug Abraxane, which is used for lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College.

Calico Life Sciences LLC is an American biotechnology company with a focus on the biology of aging, attempting to devise interventions that may enable people to lead longer and healthier lives. It is a subsidiary of Alphabet Inc.

Human Longevity, Inc. is a San Diego–based venture launched by Craig Venter, Robert Hariri and Peter Diamandis in 2013. Its goal is to build the world's most comprehensive database on human genotypes and phenotypes, and then subject it to machine learning so that it can help develop new ways to fight diseases associated with aging. The company received US$80 million in investments in its Series A offering in summer 2014 and announced a further $220 million Series B investment offering in April 2016. It has made deals with drug companies Celgene and AstraZeneca to collaborate in its research.

<span class="mw-page-title-main">Artificial intelligence in healthcare</span> Overview of the use of artificial intelligence in healthcare

Artificial intelligence in healthcare is the application of artificial intelligence (AI) to analyze and understand complex medical and healthcare data. In some cases, it can exceed or augment human capabilities by providing better or faster ways to diagnose, treat, or prevent disease.

<span class="mw-page-title-main">Insilico Medicine</span> Biotechnology company

Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company combines genomics, big data analysis, and deep learning for in silico drug discovery.

Beauty.AI is a mobile beauty pageant for humans and a contest for programmers developing algorithms for evaluating human appearance. The mobile app and website created by Youth Laboratories that uses artificial intelligence technology to evaluate people's external appearance through certain algorithms, such as symmetry, facial blemishes, wrinkles, estimated age and age appearance, and comparisons to actors and models.

<span class="mw-page-title-main">Ali Ertürk</span>

Ali Maximilian Ertürk is a neuroscientist, inventor, and artist living in Munich, Germany. He is the director of a new Helmholtz Institute on Tissue Engineering and Regenerative Medicine (iTERM) in Munich since July 2019 and professor at the medical faculty. After his undergraduate study at Bilkent University in Ankara, he joined Max-Planck-Institute for Neurobiology for his PhD and Genentech Inc. for postdoctoral research.

The Center for Security and Emerging Technology (CSET) is a think tank dedicated to policy analysis at the intersection of national and international security and emerging technologies, based at Georgetown University's School of Foreign Service.

VITAL was a Board Management Software machine learning proprietary software developed by Aging Analytics, a company registered in Bristol (England) and dissolved in 2017. Andrew Garazha declared that the project aimed "through iterative releases and updates to create a piece of software capable of making autonomous investment decisions." According to Nick Dyer-Witheford, VITAL 1.0 was a "basic algorithm".

<span class="mw-page-title-main">Amy Karle</span> American artist

Amy Karle is an American artist, bioartist, and futurist whose work focuses on the relationship between technology and humanity, specifically how technology and biotechnology impact health, humanity, society, evolution, and the future. Karle combines science and technology with art and is known for using living tissue in her work.

This timeline lists notable events in the history of research into senescence or biological aging, including the research and development of life extension methods, brain aging delay methods and rejuvenation.

The National Security Commission on Emerging Biotechnology (NSCEB) is a bipartisan U.S. legislative commission established by Congress in the 2022 National Defense Authorization Act.

Generate:Biomedicines is a biotechnology company founded in 2018 and headquartered in Cambridge, Massachusetts. It specializes in using machine learning to design and optimize proteins for therapeutic applications, with a focus on immunology, oncology, and infectious diseases.

References

  1. 1 2 3 Chace, Calum (9 November 2022). "How Insilico Medicine Uses AI To Accelerate Drug Development". Forbes Magazine .
  2. 1 2 Smyth, Jamie (26 June 2023). "Biotech begins human trials of drug designed by artificial intelligence". Financial Times .
  3. 1 2 3 4 "Alex Zhavoronkov Aims to Take Over the Drug Development World with AI". Genetic Engineering and Biotechnology News . 20 June 2023.
  4. ↑ Eric Smaley (2017). "AI-powered drug discovery captures pharma interest". Nature Biotechnology. 35 (7): 605. doi:10.1038/nbt0717-604. PMID   28700560. S2CID   205269847.
  5. ↑ Tan, Dawn; Baker, Jalelah Abu (4 January 2023). "Big investors pour funds into longevity research, accelerating growth in field". CNA.
  6. 1 2 3 4 Matsuyama, Kanoko (14 November 2023). "Race for first drug discovered by AI nears key milestone". The Japan Times .
  7. ↑ "Biogerontology Research Foundation Salutes Staff On Multi-Year Drug Development Agreement". Bioengineer.org. 14 August 2017. Retrieved 28 November 2017.
  8. ↑ Raiany Romanni, "Want to live to 150? The world needs more humans", The Boston Globe (April 2, 2023), p. K1, K5.
  9. 1 2 Scheffler, Daniel (9 July 2013). "The Ageless Generation: How Advances in Biomedicine Will Transform the Global Economy (review)". Edge Media. Archived from the original on 3 September 2014.
  10. 1 2 Tom Blackwell, "Cutting-edge science seeks treatment for age", Toronto National Post (February 6, 2021), p. As5.
  11. 1 2 3 Brazil, Rachel (7 December 2017). "Artificial Intelligence: will it change the way drugs are discovered?". Pharmaceutical Journal, the Journal of the Royal Pharmacological Society.
  12. ↑ "News: Neural network learns to select potential anticancer drugs". MIPT News. 9 February 2017.
  13. ↑ "A rather disruptive bunch". Buck Institute for Research on Aging. Retrieved 23 June 2024.
  14. ↑ USpatent 8442626B2,Alex Zavoronkov, Mikhail Bakhnyan,"Systems and methods for communicating with a computer using brain activity patterns",issued May 14, 2013
  15. ↑ Bobrov, P; Frolov, A; Cantor, C; Fedulova, I; Bakhnyan, M; Zhavoronkov, A (2011). "Brain-computer interface based on generation of visual images". PLOS ONE. 6 (6): e20674. Bibcode:2011PLoSO...620674B. doi: 10.1371/journal.pone.0020674 . PMC   3112189 . PMID   21695206.
  16. 1 2 3 4 Robbins, Tony; Diamandis, Peter H.; Hariri, Robert (2022). Life Force. Simon and Schuster. pp. 556–57. ISBN   978-1982121709.
  17. ↑ Gantz, Sarah (23 February 2017). "Insilico Medicine raises $10 million". The Baltimore Sun .
  18. ↑ Thomas, Uduak Grace (28 March 2014). "GenomeWeb: In Silico Medicine Opens US Office, Prepares to Launch Drug Discovery Software for Aging Research Market" – via www.genomeweb.com.
  19. ↑ "Skolkovo scientist says AI and blockchain could accelerate biomedical research". old.sk.ru.
  20. ↑ "Bitcoin Tech Lets People Reclaim Their Data, Says Medical Startup". Inverse. 7 December 2017.
  21. ↑ Haskins, Caroline (6 December 2017). "This Biotech Company Wants You to Give it Selfies and Blood Tests in Exchange for Cryptocurrency".
  22. 1 2 Liao, Rita (6 June 2022). "Hong Kong's AI drug discovery firm Insilico closes $60M Series D". TechCrunch .
  23. ↑ Smith, Wesley J. (8 February 2023). "Harvesting Clones to Live Forever Would Be Monstrous". National Review .
  24. ↑ Field, Hayden (29 June 2023). "The first fully A.I.-generated drug enters clinical trials in human patients". CNBC .
  25. ↑ Philippidis, Alex (20 June 2024). "Insilico Moves HQ to Cambridge, MA, Completes IPF Trial Enrollment". GEN - Genetic Engineering and Biotechnology News.
  26. ↑ Pearson, Jordan (5 September 2016). "Why An AI-Judged Beauty Contest Picked Nearly All White Winners". Motherboard. Retrieved 17 January 2017.
  27. ↑ Regalado, Antonio (20 March 2024). "An AI-driven "factory of drugs" claims to have hit a big milestone". MIT Technology Review.
  28. 1 2 Berenbaum, May R. (22 November 2023). "Welcome, AI overlords?". Proceedings of the National Academy of Sciences of the United States of America (PNAS). Vol. 120, no. 48. doi:10.1073/pnas.2318980120.
  29. ↑ Regalado, Antonio (23 May 2024). "That viral video showing a head transplant is a fake. But it might be real someday". MIT Technology Review.
  30. ↑ Google Scholar page of Alex Zhavoronkov, by publication date.
  31. ↑ PubMed Bibliography of Alex Zhavoronkov, Pubmed.
  32. ↑ "CBS Radio with Dan Raviv in Washington, DC". 9 September 2013. Event occurs at 1:45–5:20.
  33. ↑ "Interview with Aging Expert – Alex Zhavoronkov". Book Tour Radio. 20 August 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.